Pieris Pharmaceuticals Inc has entered into a new collaboration involving its proprietary protein technology in order to develop therapies for respiratory and retinal diseases. The agreement with Genentech, a member of the Roche Group, is the company’s fifth partnership since its founding in 2000, and the first in ophthalmology.
